If you are comparing options and want help deciding whether you qualify for prescription support, the assessment quiz can help you take the next step
These additional analyses provide reassurance that the conclusion of HHF benefit with empagliflozin vs DPP-4 inhibitors is robust
*Emerging evidence suggests lower-dose GLP-1 strategies may have a role in long-term weight maintenance, raising important questions around affordability, accessibility, sustainability, and chronic disease management
FDA Commissioner Marty Makary stated publicly: "We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms." The regulatory environment around GLP-1-adjacent products is tightening
Thats not peptide therapythats gambling with your health
References Demirta H, zer A, Yldrm AK, Dursun AD, Sezen C, Arslan M